company background image
NEIM

Neimeth International PharmaceuticalsNGSE:NEIMETH Stock Report

Market Cap

₦3.3b

7D

-1.7%

1Y

-2.2%

Updated

21 Oct, 2021

Data

Company Financials
NEIMETH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends2/6

NEIMETH Overview

Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical, animal health, and general healthcare products in Nigeria and Ghana.

Price History & Performance

Summary of all time highs, changes and price drops for Neimeth International Pharmaceuticals
Historical stock prices
Current Share Price₦1.76
52 Week High₦1.48
52 Week Low₦2.91
Beta0.69
1 Month Change0.57%
3 Month Change0.57%
1 Year Change-2.22%
3 Year Change258.52%
5 Year Change147.63%
Change since IPO-14.02%

Recent News & Updates

Shareholder Returns

NEIMETHNG PharmaceuticalsNG Market
7D-1.7%1.4%1.4%
1Y-2.2%39.0%41.3%

Return vs Industry: NEIMETH underperformed the NG Pharmaceuticals industry which returned 39.5% over the past year.

Return vs Market: NEIMETH underperformed the NG Market which returned 40.4% over the past year.

Price Volatility

Is NEIMETH's price volatile compared to industry and market?
NEIMETH volatility
NEIMETH Beta0.69
Industry Beta0.56
Market Beta1

Stable Share Price: NEIMETH is more volatile than 75% of NG stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NEIMETH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of NG stocks.

About the Company

FoundedEmployeesCEOWebsite
1957166Pharm. Matthew Azojihttps://www.neimethplc.com.ng

Neimeth International Pharmaceuticals Plc manufactures and markets pharmaceutical, animal health, and general healthcare products in Nigeria and Ghana. It operates through Pharmaceuticals and Animal Health segments. The company provides anti-hypertensive, blood disorders, and other products for internal organs, cardiovascular system, and chronic illnesses diseases; anti-malarial, antibiotics, and antifungals products; and multivitamins for pregnant and lactating mothers, intermittent preventive therapy (IPT) for malaria in pregnancy, and antimalarial and deworming agents.

Neimeth International Pharmaceuticals Fundamentals Summary

How do Neimeth International Pharmaceuticals's earnings and revenue compare to its market cap?
NEIMETH fundamental statistics
Market Cap₦3.34b
Earnings (TTM)₦59.68m
Revenue (TTM)₦2.82b

56.0x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEIMETH income statement (TTM)
Revenue₦2.82b
Cost of Revenue₦1.51b
Gross Profit₦1.32b
Expenses₦1.26b
Earnings₦59.68m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.031
Gross Margin46.71%
Net Profit Margin2.11%
Debt/Equity Ratio356.0%

How did NEIMETH perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

207%

Payout Ratio

Valuation

Is Neimeth International Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

56.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: NEIMETH (NGN1.76) is trading above our estimate of fair value (NGN0.25)

Significantly Below Fair Value: NEIMETH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NEIMETH is poor value based on its PE Ratio (56x) compared to the African Pharmaceuticals industry average (9.7x).

PE vs Market: NEIMETH is poor value based on its PE Ratio (56x) compared to the NG market (7.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NEIMETH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NEIMETH is overvalued based on its PB Ratio (2.7x) compared to the XF Pharmaceuticals industry average (1.5x).


Future Growth

How is Neimeth International Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neimeth International Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Neimeth International Pharmaceuticals performed over the past 5 years?

52.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEIMETH has high quality earnings.

Growing Profit Margin: NEIMETH's current net profit margins (2.1%) are lower than last year (14.4%).


Past Earnings Growth Analysis

Earnings Trend: NEIMETH has become profitable over the past 5 years, growing earnings by 52.4% per year.

Accelerating Growth: NEIMETH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: NEIMETH had negative earnings growth (-86%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: NEIMETH's Return on Equity (4.9%) is considered low.


Financial Health

How is Neimeth International Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NEIMETH's short term assets (NGN5.1B) exceed its short term liabilities (NGN2.3B).

Long Term Liabilities: NEIMETH's short term assets (NGN5.1B) exceed its long term liabilities (NGN2.9B).


Debt to Equity History and Analysis

Debt Level: NEIMETH's debt to equity ratio (356%) is considered high.

Reducing Debt: NEIMETH's debt to equity ratio has increased from 60.2% to 356% over the past 5 years.

Debt Coverage: NEIMETH's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: NEIMETH's interest payments on its debt are well covered by EBIT (8.4x coverage).


Balance Sheet


Dividend

What is Neimeth International Pharmaceuticals's current dividend yield, its reliability and sustainability?

3.69%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: NEIMETH's dividend (3.69%) is higher than the bottom 25% of dividend payers in the NG market (3.28%).

High Dividend: NEIMETH's dividend (3.69%) is low compared to the top 25% of dividend payers in the NG market (7.27%).


Stability and Growth of Payments

Stable Dividend: NEIMETH's dividend payments have been volatile in the past 10 years.

Growing Dividend: NEIMETH's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (206.9%), NEIMETH's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Pharm. Matthew Azoji

2.67yrs

Tenure

Mr. Pharm. Matthew O. Azoji is Managing Director, CEO and Member of Board at Neimeth International Pharmace since February 2019. Pharm. Azoji graduated from the Obafemi Awolowo University, Ile-Ife, Osun St...


Leadership Team

Experienced Management: NEIMETH's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: NEIMETH's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Neimeth International Pharmaceuticals Plc's employee growth, exchange listings and data sources


Key Information

  • Name: Neimeth International Pharmaceuticals Plc
  • Ticker: NEIMETH
  • Exchange: NGSE
  • Founded: 1957
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₦3.343b
  • Shares outstanding: 1.90b
  • Website: https://www.neimethplc.com.ng

Number of Employees


Location

  • Neimeth International Pharmaceuticals Plc
  • Plot 16
  • Akanni Doherty Layout
  • Lagos
  • Nigeria

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 20:58
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.